An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19

Strub-Wourgaft et al., ANTICOV, ANTICOV, Mar 2024
Progression 91% improvement lower risk ← → higher risk Hospitalization 93% HCQ for COVID-19  ANTICOV  EARLY TREATMENT RCT Is early treatment with HCQ beneficial for COVID-19? RCT 900 patients in multiple countries Trial compares with paracetamol, results vs. placebo may differ Trial underpowered to detect differences c19early.org Strub-Wourgaft et al., ANTICOV, March 2024 0 0.5 1 1.5 2+ RR
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,600+ studies for 220+ treatments. c19early.org
Meta-analysis
RCT 1,942 patients testing HCQ, lopinavir/ritonavir, nitazoxanide/ciclesonide, ivermectin/ASAQ, and fluoxetine/budesonide compared wirth paracetamol.
Paracetamol was used as a control group. Results with concurrent controls are only provided for nitazoxanide/ciclesonide. Other groups only have comparisons with the full control group. The full control group continues beyond the time of most arms, including patients at later times when COVID-19 risk was lower, therefore results may underestimate efficacy.
The nitazoxanide/ciclesonide concurrent controls are closer in time than the full group for ivermectin/ASAQ and fluoxetine/budesonide and may be a more appropriate comparison. The control group in this case shows worse results. We currently use the full control group results to be conservative.
Authors indicate that the data is available however it is not available as of May 2026.
This study is excluded in the after exclusion results of meta-analysis: significant confounding by time possible.
Important missing comments or errors? Let us know.
Study covers ivermectin, artemisinin, HCQ, budesonide, and lopinavir/ritonavir.
risk of progression, 90.8% lower, RR 0.09, p = 1.00, treatment 0 of 83 (0.0%), control 9 of 817 (1.1%), NNT 91, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), SpO2 ≤93 or death, day 21, Table 14.2.2.1.
risk of hospitalization, 93.0% lower, RR 0.07, p = 0.62, treatment 0 of 83 (0.0%), control 12 of 817 (1.5%), NNT 68, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), COVID-19 hospitalization, day 21, Table 14.2.2.13.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Strub-Wourgaft et al., 28 Mar 2024, Randomized Controlled Trial, multiple countries, preprint, 12 authors, this trial compares with another treatment - results may be better when compared to placebo, ANTICOV trial.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0